Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N S Baber

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
British Journal of Clinical Pharmacology|May 1, 1996
A new opportunity for training in clinical pharmacologyN S Baber, M J Brown
British Journal of Clinical Pharmacology|June 1, 1995
Systemic effects of glucocorticoids--a responseR W Fuller, A Bye, N S Baber
British Journal of Clinical Pharmacology|September 20, 1997
The clinical section of the British Pharmacological Society: prospects for the futureN S Baber, G T Tucker, D J Webb
British Journal of Clinical Pharmacology|August 1, 1978
Pharmacokinetic and pharmacodynamic studies with long-acting propranololJ McAinsh, N S Baber, R Smith, et al.
European Journal of Clinical Pharmacology|January 1, 1982
The use of long-acting propranolol ('Inderal' LA) in the management of elderly hypertensive patientsC Hamdy, D Tovey, N S Baber, et al.
European Journal of Clinical Pharmacology|November 27, 1978
Once daily propranolol in the treatment of mild to moderate hypertension: a dose range finding studyA P Douglas-Jones, N S Baber, A Lee
Australian and New Zealand Journal of Medicine|April 1, 1983
Beta-blockers and myocardial infarction: infarction and ischaemia in the practolol and propranolol trialsK G Green, N S Baber, J A Lewis
Biopharmaceutics & Drug Disposition|April 1, 1981
Bioavailability of propranolol and bendrofluazide formulationsJ McAinsh, B F Holmes, N S Baber, et al.
Lancet (London, England)|June 6, 1981
Beta-blockers after myocardial infarctionN S Baber, D W Evans, J A Lewis, et al.
British Medical Journal (Clinical Research Ed.)|November 24, 1984
Beta blockers after myocardial infarction: have trials changed practice?N S Baber, D G Julian, J A Lewis, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|May 1, 1996
A new opportunity for training in clinical pharmacologyN S Baber, M J Brown
British Journal of Clinical Pharmacology|June 1, 1995
Systemic effects of glucocorticoids--a responseR W Fuller, A Bye, N S Baber
British Journal of Clinical Pharmacology|September 20, 1997
The clinical section of the British Pharmacological Society: prospects for the futureN S Baber, G T Tucker, D J Webb
British Journal of Clinical Pharmacology|August 1, 1978
Pharmacokinetic and pharmacodynamic studies with long-acting propranololJ McAinsh, N S Baber, R Smith, et al.
European Journal of Clinical Pharmacology|January 1, 1982
The use of long-acting propranolol ('Inderal' LA) in the management of elderly hypertensive patientsC Hamdy, D Tovey, N S Baber, et al.
European Journal of Clinical Pharmacology|November 27, 1978
Once daily propranolol in the treatment of mild to moderate hypertension: a dose range finding studyA P Douglas-Jones, N S Baber, A Lee
Australian and New Zealand Journal of Medicine|April 1, 1983
Beta-blockers and myocardial infarction: infarction and ischaemia in the practolol and propranolol trialsK G Green, N S Baber, J A Lewis
Biopharmaceutics & Drug Disposition|April 1, 1981
Bioavailability of propranolol and bendrofluazide formulationsJ McAinsh, B F Holmes, N S Baber, et al.
Lancet (London, England)|June 6, 1981
Beta-blockers after myocardial infarctionN S Baber, D W Evans, J A Lewis, et al.
British Medical Journal (Clinical Research Ed.)|November 24, 1984
Beta blockers after myocardial infarction: have trials changed practice?N S Baber, D G Julian, J A Lewis, et al.
Pageof 3